Founded in 2019, Vanqua Bio is a biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases. With a mission to transform the lives of patients, Vanqua Bio leverages human genetics to identify key genes involved in these conditions. Their innovative drug-development approach integrates advanced insights into neuronal cell pathways and cutting-edge assays, with a primary focus on targeting glucocerebrosidase (GCase) to address unmet medical needs.
Vanqua Bio has attracted notable scientists and industry experts, contributing to its rapid progress in the field. The company has secured significant investment from leading venture capital firms, enabling robust research and development efforts. Key achievements include the advancement of their lead program targeting GCase, which holds promise for treating conditions like Parkinson's disease. Vanqua Bio's impact lies in its potential to revolutionize neurodegenerative disease treatment, offering new hope to millions of patients worldwide.
